LABORATORY NEWS
-
C2N Diagnostics And LSI Medience Partner To Bring PrecivityAD2® Alzheimer's Disease Blood Test To Japan
C2N Diagnostics, LLC (C2N) and LSI Medience Corporation (LSIM) today announced a strategic partnership to pursue regulatory approval and commercialization of PrecivityAD2 in Japan, following the test’s recent U.S. FDA clearance.
- Waters Achieves FDA 510(k) Clearance For Ready-To-Use Flow Cytometry Clinical Tests For Leukemia And Lymphoma
- One Year After Launch, Plasmidsaurus RNA-Seq Challenges RT-qPCR As The Standard For Routine Gene Expression Analysis
- Hologen And Sysmex Establish Saibogen, A Joint Venture Using AI To Turn Routine Blood Test Data Into Clinical Intelligence
- Roche Opens Up New Possibilities For Genomic Research In Asia Pacific With Next-Generation Sequencing Technology
ARCHIVED NEWSLETTER
- 10.06.26 -- QIAGEN Launches QIAmini To Automate Small-Batch Sample Preparation
- 09.22.26 -- Sakura Finetek Europe Launches Sakura Pathology Network
- 08.25.26 -- GHK-Cu Peptide Launched By Kylo Peptides For Laboratory Research Applications
- 07.21.26 -- Reassessing Nanoparticle Immunotoxicity: From Well-Established To Novel Approaches
- 07.07.26 -- A Comparison Of 6 Analytical Validation Guidelines Using Data Envelopment Analysis